133047-45-7

Basic information

• Product Name: 4-Thiazolemethanol,2-(1-methylethyl)-(9CI)
• Synonyms: 4-Thiazolemethanol,2-(1-methylethyl)-(9CI);[2-(propan-2-yl)-1,3-thiazol-4-yl]Methanol;(2-isopropylthiazol-4-yl)Methanol;2-(1-methylethyl)-4-Thiazolemethanol
• CAS NO: 133047-45-7
• Molecular Formula: C₇H₁₁NOS
• Molecular Weight: 157.236
• Product Categories: ISOPROPYL
• Mol File: 133047-45-7.mol

Chemical Properties

• Boiling Point: 252.657 °C at 760 mmHg
• Flash Point: 106.603 °C
• Appearance: /
• Density: 1.156 g/cm³
• Vapor Pressure: 0.01mmHg at 25°C
• Refractive Index: 1.55
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 13.20±0.10(Predicted)
• CAS DataBase Reference: 4-Thiazolemethanol,2-(1-methylethyl)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Thiazolemethanol,2-(1-methylethyl)-(9CI)(133047-45-7)
• EPA Substance Registry System: 4-Thiazolemethanol,2-(1-methylethyl)-(9CI)(133047-45-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 133047-45-7(Hazardous Substances Data)

Usage

Uses

Since the provided materials do not specify the uses of 4-Thiazolemethanol,2-(1-methylethyl)-(9CI), it is not possible to list its applications based on the given information. However, given its chemical structure, it may have potential applications in pharmaceuticals, chemical research, or as an intermediate in the synthesis of other compounds. Further investigation and consultation of detailed chemical databases would be necessary to determine its specific uses.

InChI:InChI=1/C7H11NOS/c1-5(2)7-8-6(3-9)4-10-7/h4-5,9H,3H2,1-2H3

Upstream product

• 133047-44-6 2-isopropyl-thiazole-4-carboxylic acid ethyl ester 
• 13515-65-6 thioisobutyramide 

Downstream Products

• 165315-49-1 (4-(hydroxymethyl)-2-isopropylthiazolyl)methyl 4-nitrophenyl carbonate 
• 133047-46-8 2-isopropyl-4-thiazolecarboxaldehyde 
• 40516-57-2 2-isopropyl-4-chloromethylthiazole 

Relevant articles and documents

THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS

Provided herein are compounds of Formula (I) and Formula (II) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of tuberculosis.

A 2 - isopropyl -4 - (methyl amino methyl) thiazole synthesis method (by machine translation)

The invention discloses a 2 - isopropyl - 4 - (methyl amino methyl) thiazole synthesis method, in order to 2, 2 - dimethyl - 4 - methylene - 1, 3 - dioxane as the starting material, with a halo reagent addition reaction with a further thio isobutyramide after condensation to produce 2 - isopropyl - 4 - hydroxymethyl thiazole, through chlorination obtained after 2 - isopropyl - 4 - chloro methyl thiazole, finally with the methylamine substitution reaction, to obtain 2 - isopropyl - 4 - (methyl amino methyl) thiazole. The method of the invention novel routes, to avoid the use of toxic chemicals as the raw material, the operation is simple, mild condition, has the potential development of industrialization. (by machine translation)

HIV protease inhibiting compounds

A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy

The structure-activity studies leading to the potent and clinically efficacious HIV protease inhibitor ritonavir are described. Beginning with the moderately potent and orally bioavailable inhibitor A-80987, systematic investigation of peripheral (P3 and P2') heterocyclic groups designed to decrease the rate of hepatic metabolism provided analogues with improved pharmacokinetic properties after oral dosing in rats. Replacement of pyridyl groups with thiazoles provided increased chemical stability toward oxidation while maintaining sufficient aqueous solubility for oral absorption. Optimization of hydrophobic interactions with the HIV protease active site produced ritonavir, with excellent in vitro potency (EC50 = 0.02 μM) and high and sustained plasma concentrations after oral administration in four species. Details of the discovery and preclinical development of ritonavir are described.